Transcriptional regulation of corticotropin-releasing hormone gene in stress response

Zhou, Jiang‐Ning; Fang, Hui

doi:10.1016/j.ibror.2018.08.003

Cited by 28 publications

(19 citation statements)

References 138 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown that a group of parvocellular neuroendocrine cells (PNCs) of the hypothalamic–pituitary–adrenal (HPA) axis the HPA axis, through somatic cells production and released into capillaries entering pituitary portal circulation, directly control pituitary corticotroph function, and downstream glucocorticoid secretion by the adrenal glands, of which most widely studied is CRH (Wamsteeker Cusulin et al, 2013). CRH has a major role in the regulation of the HPA axis, and it is the chief organizer of the body’s response to stress (Wang et al, 2011, 2013; Yang et al, 2015; Fang et al, 2016; Peng et al, 2017; Zhou and Fang, 2018). The anatomical distribution of CRH in the brain that this peptide is not only a key regulator of neuroendocrine stress, but also regulates neuronal activity in a neuromodulated manner (Dedic et al, 2018a).…”

Section: Introductionmentioning

confidence: 99%

Whole-Brain Mapping of Monosynaptic Afferent Inputs to Cortical CRH Neurons

Zhang

Yuan

et al. 2019

Front. Neurosci.

View full text Add to dashboard Cite

Corticotropin-releasing hormone (CRH) is a critical neuropeptide modulating the mammalian stress response. It is involved in many functional activities within various brain regions, among which there is a subset of CRH neurons occupying a considerable proportion of the cortical GABAergic interneurons. Here, we utilized rabies virus-based monosynaptic retrograde tracing system to map the whole-brain afferent presynaptic partners of the CRH neurons in the anterior cingulate cortex (ACC). We find that the ACC CRH neurons integrate information from the cortex, thalamus, hippocampal formation, amygdala, and also several other midbrain and hindbrain nuclei. Furthermore, our results reveal that ACC CRH neurons receive direct inputs from two neuromodulatory systems, the basal forebrain cholinergic neurons and raphe serotoninergic neurons. These findings together expand our knowledge about the connectivity of the cortical GABAergic neurons and also provide a basis for further investigation of the circuit function of cortical CRH neurons.

show abstract

Section: Introductionmentioning

confidence: 99%

Whole-Brain Mapping of Monosynaptic Afferent Inputs to Cortical CRH Neurons

Zhang

Yuan

et al. 2019

Front. Neurosci.

View full text Add to dashboard Cite

show abstract

“…The CRH gene encodes a member of the corticotropin-releasing hormone family and is mainly expressed by the hypothalamic paraventricular nucleus and secreted into the hypophyseal portal system [47]. It plays a crucial role in eliciting the stress response through stimulation of the hypothalamic, pituitary, adrenal axis and the secretion of cortisol in response to noxious stimulation [48].…”

Section: Discussionmentioning

confidence: 99%

Differential Transcription of Selected Cytokine and Neuroactive Ligand-receptor Genes in Peripheral Leukocytes from Calves in Response to Cautery Disbudding

Kongara

Dukkipati

Tai

et al. 2020

Animals

View full text Add to dashboard Cite

Calf disbudding is a painful husbandry practice on dairy and beef cattle farms. An objective measurement of pain is useful to reliably evaluate the pain intensity and anti-nociceptive (analgesic) efficacy of therapeutic agents. The aim of this study was to investigate the changes in peripheral leucocyte inflammatory cytokine gene expression in calves after disbudding, and to assess whether the changes in cytokine gene expression could be an indicator of the efficacy of analgesic drugs. In a randomised controlled study, 16 calves (aged 31 to 41 days and weighing 58 to 73 kg), undergoing routine disbudding, were randomly allocated into two groups (n = 8 in each group). Calves in the control group received no analgesic, while those in the treatment group received 0.5 mg kg−1 meloxicam subcutaneously prior to disbudding. Disbudding was performed using an electric debudder. Blood (10 mL) was sampled from the jugular vein just before and 4 and 24 h post-disbudding, RNA was extracted from leukocytes, and the transcription of 12 genes of interest was assessed using nCounter gene expression assay. The results showed significantly higher transcription (compared to baseline values) of the studied genes (except CRH, IFNγ, and IL10) in the control group calves at either 4 or 24 h post-disbudding. The administration of meloxicam one hour before disbudding significantly attenuated the upregulation of IL6, PGHS2, TAC1, NOS1, and CRH gene transcription post-disbudding, while it did not suppress the elevated transcription of acute and pro-inflammatory cytokines such as IL1β, IFNγ, IL8, and TNFα genes. In conclusion, nCounter gene expression assay seems to be a promising tool to study the expression of cytokine genes and thus could be used for the pre-clinical evaluation of novel analgesics.

show abstract

“…et al observed no significant difference in total testosterone, LH, or FSH with isotretinoin therapy [23]. Similarly, Marynick et al found no statistically significant changes in serum DHEAS, total testosterone, LH, or FSH with isotretinoin therapy [24].…”

Section: Discussionmentioning

confidence: 99%

Untitled

2020

Our Dermatol Online

View full text Add to dashboard Cite

Acitretin is a second-generation oral retinoid used by dermatologists for the treatment of dermatological disorders such as psoriasis, pityriasis rubra pilaris, and lichen planus [1]. Acitretin may cause some common side effects such as dry skin and mucosa, hyperlipidemia, muscle and joint pain, and hepatitis [2]. Erectile dysfunction is defined as the inability to achieve and maintain a penile erection adequate for satisfactory sexual intercourse. Erectile dysfunction may be due to various reasons, including psychogenic and organic factors, endocrine disorders, and drug use [3]. Data on the effect of acitretin on sexual function is limited. The literature provides no studies that would investigate whether acitretin causes erectile dysfunction in humans. Therefore, in this study, we aimed at investigating whether patients taking acitretin develop erectile dysfunction. MATERIALS AND METHODS The study included 40 male patients who presented to the Dermatology Polyclinic of Okmeydanı Training and Research Hospital between October 2014 and April 2016 and started treatment with acitretin for various dermatological disorders. Exclusion criteria included psychogenic and psychiatric disorders, diabetes mellitus, ABSTRACT Background: Acitretin is a second-generation oral retinoid compound used as a treatment option for various dermatological disorders. The effects of the drug on erectile function have not been fully determined yet. We aimed at investigating whether patients taking acitretin develop erectile dysfunction (ED). Materials and Methods: The study included 40 male patients who presented to the Dermatology Polyclinic of Okmeydanı Training and Research Hospital between October 2014 and April 2016 and started treatment with acitretin. Exclusion criteria included psychogenic and psychiatric disorders, neurological disorders such as multiple sclerosis, diabetes mellitus and endocrine disorders, arteriogenic and venous disorders, alcohol and tobacco use, penile disorders, obesity, a history of drug use, a score of above 10 points in the Beck Depression Inventory (BDI), hyperlipidemia, and an age above 65 years. Having obtained the informed consent, the patients were asked to complete the International Index of Erectile Function (IIEF) questionnaire before and after three months of therapy. The patients were evaluated by calculating their scores and a statistical analysis was performed. Results: A total of 40 patients were included in the study. A comparison of the IIEF scores before and after three months of therapy revealed that the scores were significantly lower after three months of therapy (P < 0.0001). ED was diagnosed in 30 patients (75%) at the beginning of therapy and in 35 patients (87.5%) after three months of therapy. A comparison of baseline and 3-month IIEF grades revealed that the number of patients in the second group was significantly greater after three months of therapy with the drug (P = 0.001). When the percentage of patients with erectile dysfunction at the baseline and after three months of ther...

show abstract

Transcriptional regulation of corticotropin-releasing hormone gene in stress response

Cited by 28 publications

References 138 publications

Whole-Brain Mapping of Monosynaptic Afferent Inputs to Cortical CRH Neurons

Whole-Brain Mapping of Monosynaptic Afferent Inputs to Cortical CRH Neurons

Differential Transcription of Selected Cytokine and Neuroactive Ligand-receptor Genes in Peripheral Leukocytes from Calves in Response to Cautery Disbudding

Untitled

Contact Info

Product

Resources

About